- The Washington Times - Wednesday, June 21, 2006

CHICAGO (AP) — Statins, the cholesterol-lowering drugs that millions of Americans take, also might reduce the risk of cataracts, a preliminary study suggests.

Adults who took statins were found to be 45 percent less likely to develop the most common type of age-related cataracts.

Other researchers warned that something other than statins might explain the results and that the study does not prove a cause-and-effect relationship.

The results were a surprise because of earlier concerns that some cholesterol medication might increase the risk of cataracts, a common clouding of the lens of the eye that can lead to poor vision and blindness. In fact, several cholesterol drugs never made it to market because of those concerns.

The study, published in today’s Journal of the American Medical Association, involved 1,299 Beaver Dam, Wis., residents who were followed for five years.

Nuclear cataracts — which affect the eye lens nucleus — were diagnosed in more than 200 participants, or in about 12 percent of statin users, compared with 17 percent of nonusers. After factoring in the participants’ ages, researchers concluded that statin users were about 45 percent less likely to develop nuclear cataracts.

“It was pretty surprising,” said lead author Dr. Barbara Klein, an eye researcher at the University of Wisconsin at Madison.

No statistically significant differences in rates were reported for two other less-common types of cataracts.

Statins, which millions of Americans take and include such top-selling drugs as Lipitor, Pravachol and Zocor, dramatically lower levels of artery-clogging bad cholesterol.

Statins also have been reported to have antioxidant benefits and to attack inflammation. Both oxygen damage to the body and inflammation are thought to be related to cataracts.

Cataracts affect more than 20 million Americans and are a major cause of vision impairment and blindness worldwide. Most are associated with aging; more than half of U.S. adults in their 70s and older are affected.

In the latest study, the statin-cataract relationship remained strong even when the researchers factored in whether participants smoked, a habit that is linked to the development of cataracts.

But Debra Schaumberg, an eye specialist at Harvard’s Brigham and Women’s Hospital, cautioned against overinterpreting the results.

“While I agree with the authors that the potential for a relatively benign and inexpensive preventive therapy for cataract would have substantial public health importance, I think it is still far too early to assign any such role to statin medications,” she said.

Similarly, researcher Natalie Kurinij of the National Eye Institute, which helped fund the study, said the results do not mean that people should take statins to ward off cataracts.

“There was no information on duration of use or the doses used. You would really need that kind of information in order to make a definitive call,” she said.

Sign up for Daily Newsletters

Manage Newsletters

Copyright © 2021 The Washington Times, LLC. Click here for reprint permission.

Please read our comment policy before commenting.


Click to Read More and View Comments

Click to Hide